UCCT-BCMA-1 / University of California - LARVOL DELTA

Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting (The Malaysian Reserve) - "The Parker Institute for Cancer Immunotherapy (PICI), today announced that research and expertise from across its network will be showcased at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 5–9 in National Harbor, Maryland. PICI leaders, investigators and collaborators are contributing to 80 posters, presentations and discussions throughout the 40th anniversary program"

Clinical data • Multiple Myeloma

UCCT-BCMA-1: A First-in-Human, Non-Viral CRISPR-Engineered CAR T Cell Therapy Targeting BCMA in Relapsed/Refractory Multiple Myeloma (SITC 2025) - "Its non-viral manufacturing platform enhances safety, scalability, and patient accessibility. Importantly, this program is part of an open-source sharing network, enabling broader access to protocols, data, and technology to accelerate the development of safe and effective gene-edited cell therapies across the field.Ethics Approval All animal studies conducted followed a protocol approved by the UCSF Institutional Animal Care and Use Committee.Abstract 247 Figure 1Request permissionsOverview of non-viral engineering platform"

CAR T-Cell Therapy • First-in-human • IO biomarker • P1 data • Hematological Malignancies • Multiple Myeloma • Oncology • CD4 • CD5 • CD8

Development of a 1XX-Enhanced and Fully Non-Viral, CRISPR-edited BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1) (ASGCT 2025) - "We plan to make the manufacturing SOPs and critical study reports publicly available to enable widespread use of this platform and improve access to cutting edge therapies in the academic setting. Disease Focus of Abstract:Myeloma"

CAR T-Cell Therapy • Hematological Malignancies • Multiple Myeloma • Oncology